Reply to "Matters arising: cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer: a modelling approach".

Wen Hui, Zhixiang Gao, Min Zhu, Huazhang Wu, Yuanyi Cai

Abstract readLetter

In one paragraph

Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Wen HuiDepartment of Science and Techonology, West China Hospital of Sichuan University, Chengdu, China.

Zhixiang GaoDepartment of Pharmacy, Affiliated Central Hospital of Shenyang Medical College, Shenyang, China.

Min ZhuDepartment of Health Service Management, School of Health Management, China Medical University, Shenyang, China.

Huazhang WuSchool of Medical Humanities Sciences, China Medical University, Shenyang, China.

Yuanyi CaiDepartment of Health Service Management, School of Health Management, China Medical University, Shenyang, China. yycai@cmu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this article, we read with great attention the correspondence by Bullement et al., regarding our published study on cost-effectiveness of first-line immunotherapy combinations with or without chemotherapy for advanced non-small cell lung cancer. We referred to a few the most important comments from Bullement et al. in our opinion, including proportional hazard (PH) assumption, accelerated failure time (AFT) model, and health utility, and made some explanations.

Indexed as

Carcinoma, Non-Small-Cell LungCost-Benefit AnalysisImmunotherapyLung NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsHumansAccelerated failure time modelHealth utilityProportional hazard

Identifiers

PMID39039454

DOI10.1186/s12885-024-12288-5

PMCPMC11265065

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.